On this page
Desonide Ointment, 0.05%
Overview
Active ingredients
Source: NDC Directory| Ingredient | Strength | RxCUI | Monograph |
|---|---|---|---|
| Desonide | .5 mg/g | 204135 | View |
Forms, strengths and routes
Source: NDC DirectoryPharmacologic classes are listed in the class section below.
Pharmacologic class
Source: NDC Directory| Class | Type | Browse |
|---|---|---|
| Corticosteroid Hormone Receptor Agonists [MoA] | MoA | All 215 members |
| Corticosteroid [EPC] | EPC | All 215 members |
Regulatory status
Source: Drugs@FDANDC Directory| Product | Trade name | Form | Strength | Ingredient | Status | TE | Flags |
|---|---|---|---|---|---|---|---|
| 210998-001 | DESONIDE | OINTMENT | DESONIDE | Prescription | AB |
Therapeutic equivalence
Source: Orange BookWhat this rating means: Therapeutically equivalent — bioequivalence demonstrated by in vivo or in vitro testing
Codes beginning with “A” indicate products the FDA considers therapeutically equivalent. Codes beginning with “B” indicate bioequivalence has not been established. See methodology.
Approval history
Source: Drugs@FDA| Type | No. | Action | Status | Date | Review |
|---|---|---|---|---|---|
| Original application | 1 | Approved | January 30, 2019 | Standard |
Prescribing information
Source: openFDA Drug LabelingReproduced verbatim from the Structured Product Labeling submitted to the FDA (effective 20260528). This is the manufacturer's labelling text, not a summary and not advice.
Indications and Usage
openFDA Drug LabelingINDICATIONS AND USAGE Desonide ointment USP, 0.05% is a low potency corticosteroid indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid responsive dermatoses. It should not be used for longer than two weeks unless directed by a physician.
Dosage and Administration
openFDA Drug LabelingDOSAGE AND ADMINISTRATION Desonide Ointment, 0.05% should be applied to the affected area as a thin film from two to four times daily depending on the severity of the condition. As with other corticosteroids, therapy should be discontinued when control is achieved. If no improvement is seen within two weeks, reassessment of diagnosis may be necessary. Desonide Ointment, 0.05% should not be used with occlusive dressings.
Contraindications
openFDA Drug LabelingCONTRAINDICATIONS Desonide Ointment, 0.05% is contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
Adverse Reactions
openFDA Drug LabelingADVERSE REACTIONS In controlled clinical trials, the total incidence of adverse reactions associated with the use of Desonide Ointment, 0.05% was approximately 6%. These adverse reactions were erythema, induration, pruritus, irritation, oiliness, and peripheral edema. The following additional local adverse reactions have been reported infrequently with topical corticosteroids, and they may occur more frequently with the use of occlusive dressings and higher potency corticosteroids. These reactions are listed in approximate decreasing order of occurrence: dryness, folliculitis, acneiform eruptions, perioral dermatitis, allergic contact dermatitis, secondary infection, skin atrophy, striae, miliaria, burning and hypopigmentation. To report SUSPECTED ADVERSE REACTIONS , contact Encube Ethicals Private Limited at 1-833-285-4151 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Description
openFDA Drug LabelingDESCRIPTION Desonide ointment USP, 0.05% contains desonide (Pregna-1,4-diene-3,20-dione,11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-,(11ß,16α)) a synthetic corticosteroid for topical dermatologic use. The corticosteroids constitute a class of primary synthetic steroids used topically as anti-inflammatory and antipruritic agents. Chemically, desonide, the active ingredient in desonide ointment USP, 0.05% is C 24 H 32 O 6 . It has the following structural formula: The molecular weight of desonide is 416.51. It is white to off-white powder. The solubility of desonide in distilled water saturated with the ether is 184 mg/L. Each gram of desonide ointment USP, 0.05% contains 0.5 milligram of desonide microdispersed in a base of white petrolatum. structure.jpg
Overdosage
openFDA Drug LabelingOVERDOSAGE Topically applied Desonide Ointment, 0.05% can be absorbed in sufficient amounts to produce systemic effects (see PRECAUTIONS ).
How Supplied / Storage and Handling
openFDA Drug LabelingHOW SUPPLIED Desonide ointment USP, 0.05% is available as follows: 15 g tube (NDC 21922-004-04) 60 g tube (NDC 21922-004-07) STORAGE Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature]. Product of Italy Manufactured by: Encube Ethicals Pvt. Ltd. Plot No. C1, Madkaim Industrial Estate, Madkaim, Post Mardol, Ponda, Goa-403 404, India. Distributed by: Encube Ethicals, Inc. 200 Meredith Drive, Suite 202, Durham, NC 27713 USA Rev. 11/25
Adverse event reports
Source: openFDA FAERSAttributed to this product's most-reported active ingredient: DESONIDE. Combination products with more than six active ingredients are not attributed, because a report count summed across a long ingredient list measures the list, not the medicine.
Packaging and NDCs
Source: NDC Directory| Package NDC | Product NDC | Labeler | Description | Marketing start |
|---|---|---|---|---|
| 63629-8481-1 | 63629-8481 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8481-1) / 60 g in 1 TUBE | March 20, 2019 |
| 63629-8482-1 | 63629-8482 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (63629-8482-1) / 15 g in 1 TUBE | March 20, 2019 |
| 72162-1272-2 | 72162-1272 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1272-2) / 15 g in 1 TUBE | March 20, 2019 |
| 72162-1272-6 | 72162-1272 | Bryant Ranch Prepack | 1 TUBE in 1 CARTON (72162-1272-6) / 60 g in 1 TUBE | March 20, 2019 |
| 21922-004-04 | 21922-004 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-004-04) / 15 g in 1 TUBE | March 20, 2019 |
| 21922-004-07 | 21922-004 | Encube Ethicals, Inc. | 1 TUBE in 1 CARTON (21922-004-07) / 60 g in 1 TUBE | March 20, 2019 |
| 63629-8481 | 63629-8481 | Bryant Ranch Prepack | — | March 20, 2019 |
| 63629-8482 | 63629-8482 | Bryant Ranch Prepack | — | March 20, 2019 |
| 72162-1272 | 72162-1272 | Bryant Ranch Prepack | — | March 20, 2019 |
| 21922-004 | 21922-004 | Encube Ethicals, Inc. | — | March 20, 2019 |
Sources for this page
| Dataset | Agency | Used for |
|---|---|---|
| NDC Directory | FDA | Identity, ingredients, strengths, forms, routes, labelers, packages |
| Drugs@FDA | FDA | Application, sponsor, submissions, review documents, marketing status |
| Orange Book | FDA | Therapeutic equivalence codes, reference drug flags, patents, exclusivity |
| Drug Labeling | FDA / NLM | Prescribing information reproduced above |
| FAERS | FDA | Adverse event report counts |
Generated September 25, 2026 · 11 sections on this page.